Taking Advantage of Sub-2 ?m Core–Shell Technology for Ultra-Fast and Ultra-Efficient Urinary Excretion Profiling

September 1, 2012

The Application Notebook

The Application Notebook, The Application Notebook-09-01-2012, Volume 0, Issue 0

Throughout the drug development process, potential new drug candidates (or new chemical entities; NCEs) and their metabolites must be subjected to rigorous and extensive pharmacokinetic evaluations to determine their rates accumulation, metabolism, and excretion from the body. With regards specifically to the excretion, urinary excretion is typically the predominant route for the elimination of drugs and their metabolites, and urinary excretion profiling is an integral portion of the pharmacokinetic characterization of NCEs.

Throughout the drug development process, potential new drug candidates (or new chemical entities; NCEs) and their metabolites must be subjected to rigorous and extensive pharmacokinetic evaluations to determine their rates accumulation, metabolism, and excretion from the body. With regards specifically to the excretion, urinary excretion is typically the predominant route for the elimination of drugs and their metabolites, and urinary excretion profiling is an integral portion of the pharmacokinetic characterization of NCEs.

Liquid chromatography tandem mass spectroscopy (LC–MS-MS) allows scientists to rapidly and accurately quantify specific drugs and their metabolites at extremely low levels from various biological matrices, such as urine. On the liquid chromatography side, the ultra-high efficiency delivered by sub-2 μm UHPLC core–shell media provides analysts with the ability to run their samples in extremely short periods of time while maintaining excellent resolution from sample interferences. In this application note, we present an example of the ability of the Kinetex® 1.7 μm core–shell particle to deliver significantly improved performance over larger core–shell particles and conventional fully porous media.

Experimental Conditions

LC–MS-MS conditions

Column: Kinetex 1.7 μm C18 30 × 2.1 mm Fused-core 2.7 μm C18 50 × 2.1 mm Fully porous 3.5 μm C18 50 × 2.1 mm

Mobile Phase: A: 10 mM Ammonium formate B: Acetonitrile

Gradient: (95:5) A/B to (0:100) A/B in 2 min, then re-equilibrate at (95:5) A/B for 1 min

Flow Rate: 700 μL/min

Temperature: Ambient

Detection: MS using API 4000 detector

HPLC system: Agilent 1200 SL

Concentration: 100 ng/mL for active drug and 50 ng/mL for metabolite

Analytes: Lorazepam-glucuronide spiked into urine at a concentration of 50 ng/mL

Figure 1: XIC for oxazepam glucuronide (MRM 463.1 -> 287.0) in urine.

Results

In many instances, suitable MRM transitions for an analyte of interest are hidden because of significant matrix interference. Oxazepam-glucuronide did not suffer from urinary interference (Figure 1), however the 497.2 -> 320.9 MRM transition for the glucuronide metabolite of lorazepam does show significant isobaric interference (Figure 2). In cases such as this, the ultra-high efficiency of the core–shell Kinetex 1.7 μm particle can provide significantly greater peak capacity than standard fully-porous media (3.5 μm in this case) and a larger fused-core particle (2.7 μm fused-core).

Figure 2: Comparison of the performance of the Kinetex 1.7 μm C18 (30 × 2.1 mm) column versus a fused-core 2.7 μm column (50 × 2.1 mm) and a fully porous 3.5 μm C18 column (50 × 2.1 mm) for the glucuronide metabolite of lorazepam (MRM 497.2 -> 320.9).

Phenomenex Inc.

411 Madrid Avenue, Torrance, CA 90501

tel. (310) 212-0555, (310) 328-7768

Website: www.phenomenex.com